Literature DB >> 9200449

Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression.

E Chuang1, M L Alegre, C S Duckett, P J Noel, M G Vander Heiden, C B Thompson.   

Abstract

CTLA-4 is a lymphocyte cell surface receptor expressed by activated T cells that functions to down-regulate T cell responses induced by TCR and CD28 stimulation. Since CTLA-4 competes with CD28 for binding to the common ligands B7-1 and B7-2, the level of CTLA-4 surface expression is likely to play an important role in its ability to inhibit CD28-dependent T cell activation. The factors that regulate these levels are poorly understood. Recent studies have revealed that following T cell activation, the majority of CTLA-4 is localized intracellularly rather than on the cell surface, and surface CTLA-4 is rapidly reinternalized. In this study, we investigate the molecular mechanism underlying the rapid clearance of CTLA-4 from the cell surface. The data demonstrate that cell surface CTLA-4 is endocytosed into clathrin-coated vesicles even in the absence of ligand. The targeting of CTLA-4 to clathrin-coated vesicles is mediated by the clathrin-associated adaptor complex AP-2. The cytoplasmic domain of CTLA-4 was found to specifically bind to AP50, the medium chain subunit of AP-2 in both yeast two-hybrid and coimmunoprecipitation assays. The interaction requires the peptide sequence 199-GVYVKM-204 in the cytoplasmic tail of CTLA-4. Mutation of the CTLA-4 amino acid residue Y201 abrogates the interaction with AP50, resulting in the accumulation of CTLA-4 at the cell surface. Together these data suggest that the interaction of CTLA-4 with AP50 plays an important role in regulating the cell surface expression of CTLA-4.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200449

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

1.  Study of the interaction of the medium chain mu 2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28.

Authors:  E R Follows; J C McPheat; C Minshull; N C Moore; R A Pauptit; S Rowsell; C L Stacey; J J Stanway; I W Taylor; W M Abbott
Journal:  Biochem J       Date:  2001-10-15       Impact factor: 3.857

Review 2.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 3.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Conservation and diversification of dileucine signal recognition by adaptor protein (AP) complex variants.

Authors:  Rafael Mattera; Markus Boehm; Rittik Chaudhuri; Yogikala Prabhu; Juan S Bonifacino
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

Review 5.  Testing for endocytosis in plants.

Authors:  F Aniento; D G Robinson
Journal:  Protoplasma       Date:  2005-10-20       Impact factor: 3.356

Review 6.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

7.  The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization.

Authors:  Rui Jia; Qinghua Pan; Shilei Ding; Liwei Rong; Shan-Lu Liu; Yunqi Geng; Wentao Qiao; Chen Liang
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

8.  CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Authors:  Kavita V Shah; Andy J Chien; Cassian Yee; Randall T Moon
Journal:  J Invest Dermatol       Date:  2008-06-19       Impact factor: 8.551

9.  Dileucine and YXXL motifs in the cytoplasmic tail of the bovine leukemia virus transmembrane envelope protein affect protein expression on the cell surface.

Authors:  Sinisa Novakovic; Earl T Sawai; Kathryn Radke
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 10.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.